Business Context and Reporting Period
Company: PolyPid Ltd. (PYPD)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: PolyPid is an Israeli biopharmaceutical company developing long-acting, controlled-release medicines using its proprietary PLEX and Kynatrix technologies. The company has no approved products and generates no revenue. Its lead product candidate, D-PLEX 100, is designed to prevent surgical site infections (SSIs) by delivering doxycycline directly to the surgical site for 30 days.
Key Financial Metrics
| Metric | 2025 (in thousands) | 2024 (in thousands) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(34,169) | $(29,022) |
| Operating Loss | $(32,967) | $(28,029) |
| Cash and Cash Equivalents (Dec 31, 2025) | $6,402 | $15,641 |
| Total Cash, Equivalents & Short-Term Deposits | $12,900 | $15,641 |
| Accumulated Deficit | $(301,500) | $(267,331) |
| Outstanding Debt (Principal) | $0.7 million (as of Feb 19, 2026) | $7.4 million (Dec 31, 2024) |
| Ordinary Shares Outstanding | 18,204,002 | 10,190,904 |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $5.1 million (18%) year-over-year, driven by higher operating expenses.
- Expense Growth:
- Research & Development (R&D): Increased by $1.0 million to $23.8 million, primarily due to NDA submission preparation and personnel costs, partially offset by the completion of the SHIELD II trial.
- General & Administrative (G&A): Increased by $2.9 million to $7.2 million, driven by share-based compensation and legal/professional fees.
- Marketing & Business Development: Increased by $1.0 million to $2.0 million.
- Capital Structure: Significant equity issuance occurred in 2025, including an "Inducement Letter" transaction where holders exercised existing warrants for approximately $26.7 million in net proceeds in exchange for new warrants. Shares outstanding increased by roughly 79%.
- Debt Reduction: The company significantly reduced its Kreos Capital loan principal through repayments and restructuring, with only $0.7 million outstanding as of February 2026.
- Asset Capitalization: The company capitalized $1.1 million in pre-launch inventory for the first time, reflecting the probability of regulatory approval following positive trial results.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Regulatory Milestone: In June 2025, the company announced positive topline results from the pivotal SHIELD II Phase 3 trial for D-PLEX 100, meeting primary and key secondary endpoints. The FDA pre-NDA meeting in December 2025 supported an NDA submission.
- NDA Submission: The company expects to submit a New Drug Application (NDA) on a rolling basis beginning in Q1 2026, leveraging Fast Track and Breakthrough Therapy designations.
- Liquidity: Management expects existing cash resources to fund operations into the second half of 2026. However, the company anticipates needing substantial additional funding to complete the NDA process and commercialize the product.
- Pipeline Expansion: The company unveiled a long-acting GLP-1 receptor agonist delivery platform and continues to develop OncoPLEX for oncology applications.
Risks and Contingencies
- Going Concern: The independent auditor has issued an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for additional financing.
- Regulatory Approval: There is no guarantee that the NDA will be approved, or that the FDA will accept the data from the SHIELD II trial as sufficient for the requested indications.
- Capital Requirements: Failure to raise additional capital on acceptable terms could force the company to curtail or discontinue operations.
- Geopolitical Risk: Operations are based in Israel, exposing the company to risks related to regional military conflict and political instability.
Key Facts for Investor Verification
- Cash Runway: Verify the specific timeline for cash burn and the sufficiency of the $12.9 million in liquid assets to fund operations through the NDA submission and potential commercial launch.
- NDA Acceptance: Monitor the FDA's acceptance of the rolling NDA submission and any requests for additional data or clinical trials.
- Financing Terms: Review the terms of any future equity or debt financing, particularly regarding dilution and covenants, given the current "going concern" warning.
- Commercial Partnerships: Assess the status of commercialization agreements, particularly the existing license with Advanz Pharma for the EEA/UK and potential US partners.
- Debt Covenants: Confirm the status of the Kreos Capital loan, specifically the "claw-back" provisions and any remaining obligations.